C4 Therapeutics Inc
CCCC2.110USD
-0.270-11.34%
Cierre 07/15, 16:00（ET）Cotizaciones retrasadas 15 min
149.79MCap. mercado
PérdidaP/E TTM
Más Datos de C4 Therapeutics Inc Compañía
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Información de la empresa
Símbolo de cotizaciónCCCC
Nombre de la empresaC4 Therapeutics Inc
Fecha de salida a bolsaOct 02, 2020
Fundada en2015
Director ejecutivoMr. Andrew J. Hirsch
Número de empleados110
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 02
Dirección490 Arsenal Way
CiudadWATERTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02472
Teléfono16172310700
Sitio Webhttps://c4therapeutics.com/
Símbolo de cotizaciónCCCC
Fecha de salida a bolsaOct 02, 2020
Fundada en2015
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Courtney Solberg
Ms. Courtney Solberg
Senior Manager - Investor Relations
Senior Manager - Investor Relations
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Wasatch Global Investors Inc
10.52%
Lynx1 Capital Advisors LLC
10.00%
Soleus Capital Management, L.P.
9.83%
OrbiMed Advisors, LLC
9.62%
Betta investment Hong Kong Ltd
6.86%
Other
53.17%
Accionistas
Accionistas
Proporción
Wasatch Global Investors Inc
10.52%
Lynx1 Capital Advisors LLC
10.00%
Soleus Capital Management, L.P.
9.83%
OrbiMed Advisors, LLC
9.62%
Betta investment Hong Kong Ltd
6.86%
Other
53.17%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
27.67%
Investment Advisor
23.98%
Hedge Fund
21.97%
Private Equity
9.62%
Research Firm
7.68%
Corporation
6.86%
Individual Investor
3.27%
Bank and Trust
0.80%
Pension Fund
0.14%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
309
72.46M
102.05%
-13.77M
2025Q1
338
73.30M
106.72%
-7.68M
2024Q4
337
73.17M
103.10%
-6.50M
2024Q3
332
72.91M
103.31%
-3.42M
2024Q2
325
69.49M
100.73%
-3.96M
2024Q1
329
66.54M
97.72%
+3.15M
2023Q4
324
51.20M
103.91%
-2.36M
2023Q3
320
38.85M
79.00%
-14.16M
2023Q2
326
38.30M
78.08%
-12.52M
2023Q1
331
41.73M
85.11%
-15.41M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Wasatch Global Investors Inc
7.47M
10.52%
+748.92K
+11.14%
Apr 30, 2025
Lynx1 Capital Advisors LLC
7.10M
10%
+245.39K
+3.58%
Mar 31, 2025
Soleus Capital Management, L.P.
6.98M
9.83%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
6.83M
9.62%
+2.45M
+56.02%
Mar 31, 2025
Betta investment Hong Kong Ltd
4.87M
6.86%
-693.38K
-12.45%
Apr 22, 2025
BlackRock Institutional Trust Company, N.A.
4.72M
6.65%
-159.63K
-3.27%
Mar 31, 2025
The Vanguard Group, Inc.
3.37M
4.75%
+24.91K
+0.74%
Mar 31, 2025
Samlyn Capital, LLC
3.02M
4.25%
-4.32K
-0.14%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.45M
3.45%
-819.05K
-25.05%
Mar 31, 2025
BofA Global Research (US)
1.99M
2.8%
+313.18K
+18.67%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
Fidelity Enhanced Small Cap ETF
Proporción0.01%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
